Sonnet Biotherapeutics Holdings Stock Today
| SONN Stock | USD 2.61 0.04 1.56% |
Performance0 of 100
| Odds Of DistressOver 82
|
Sonnet Biotherapeutics is selling at 2.61 as of the 3rd of December 2024; that is 1.56 percent increase since the beginning of the trading day. The stock's open price was 2.57. Sonnet Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Sonnet Biotherapeutics Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of December 2022 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of October 2006 | Category Healthcare | Classification Health Care |
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey. Sonnet BioTherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 837.66 K outstanding shares of which 35.2 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. More on Sonnet Biotherapeutics Holdings
Moving together with Sonnet Stock
Moving against Sonnet Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Fiscal Year End 12th of December 2024
Sonnet Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman, Founder | Pankaj Mohan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSonnet Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sonnet Biotherapeutics' financial leverage. It provides some insight into what part of Sonnet Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sonnet Biotherapeutics Holdings (SONN) is traded on NASDAQ Exchange in USA. It is located in 100 Overlook Center, Princeton, NJ, United States, 08540 and employs 12 people. Sonnet Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.19 M. Sonnet Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 837.66 K outstanding shares of which 35.2 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover.
Sonnet Biotherapeutics Holdings currently holds about 5.22 M in cash with (21.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21.
Check Sonnet Biotherapeutics Probability Of Bankruptcy
Ownership AllocationSonnet Biotherapeutics has 4.22 % of its outstanding shares held by insiders and 0.61 % owned by institutional holders.
Check Sonnet Ownership Details
Sonnet Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 0.0 | |
| Private Wealth Management Group Llc | 2024-09-30 | 0.0 | |
| Sabby Management Llc | 2024-06-30 | 238.4 K | |
| Virtu Financial Llc | 2024-06-30 | 32.7 K | |
| Blackrock Inc | 2024-06-30 | 520 | |
| Tower Research Capital Llc | 2024-09-30 | 378 | |
| Bank Of America Corp | 2024-06-30 | 28.0 | |
| Susquehanna International Group, Llp | 2024-06-30 | 0.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Citigroup Inc | 2024-06-30 | 0.0 |
Sonnet Biotherapeutics Historical Income Statement
Sonnet Stock Against Markets
Sonnet Biotherapeutics Corporate Management
| Manuel Dafonseca | Head Operations | Profile | |
| Stephen McAndrew | Senior Development | Profile | |
| Gael Hedou | Chief Officer | Profile | |
| John Cini | Chief CoFounder | Profile | |
| MD FACP | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.